Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP

{
  "signal_id": "ddac98f0-2778-b390-8ccd-3b614beb8612",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-08-29T20:14:30+00:00",
  "company": {
    "name": "Regeneron",
    "domain": "regeneron.com"
  },
  "data": {
    "url": "https://finance.yahoo.com/healthcare/articles/regeneron-pharmaceuticals-regn-wins-fda-201430933.html",
    "title": "Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP - Yahoo Finance",
    "excerpt": "Regeneron Pharmaceuticals (NasdaqGS: REGN) received FDA approval for Pasatru TM (garetosmab grts) to treat adults with fibrodysplasia ossificans progressiva. The approval is based on a positive Phase 3 trial in this rare and severely debilitating condition. Pasatru adds a new rare disease therapy to Regeneron's portfolio and introduces a fresh product-based revenue stream. This kind of targeted drug development in rare diseases is part of a wider shift toward more data driven healthcare, which many investors explore further through 39 healthcare AI stocks . Regeneron Pharmaceuticals is a US based biotech company with a US$80.7b market cap that develops, manufactures, and commercializes medicines across a range of diseases. This rare disease approval sits alongside its broader drug portfolio, which is a key part of how the company positions itself within large cap biotechs. We've flagged 0 risks for Regeneron Pharmaceuticals. See which could impact your investment. For investors, Pasatru fits neatly into Regeneron Pharmaceuticals' Narrative of using core immunology cash flows to support a broader pipeline. It reinforces the catalyst that an expanding portfolio across immunology and genetic medicine can diversify revenue away from heavier reliance on EYLEA. The FOP indication is very small, so the near term financial impact is likely modest in the context of a US$80.7b company...",
    "product": "Pasatru",
    "summary": "Regeneron Pharmaceuticals received FDA approval for its drug Pasatru (garetosmab grts) to treat adults with fibrodysplasia ossificans progressiva (FOP).",
    "location": "United States",
    "planning": false,
    "image_url": "https://s.yimg.com/lo/mysterio/api/7fc4fa2c5ac11b68a39ffd824cad6fdaac778d6bff561179e95337ccbd70e7c0/lightyear_networkapi/resizefill_w1200%3Bquality_80%3Bformat_webp/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fsimply_wall_st__316%2Fa52f4d4b48157c0b8b51190845e3ba14.jpg",
    "confidence": 0.95,
    "product_data": {
      "name": "Pasatru",
      "full_text": "Pasatru TM (garetosmab grts)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-08-29T20:14:30Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Regeneron Pharmaceuticals (NasdaqGS: REGN) received FDA approval for Pasatru TM (garetosmab grts) to treat adults with fibrodysplasia ossificans progressiva."
  }
}

curl https://signals.autobound.ai/v1/signals/ddac98f0-2778-b390-8ccd-3b614beb8612 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"regeneron.com","limit":20}'